Opioid Use Disorders
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Braeburn PharmaceuticalsPA - Plymouth Meeting
1 program1
CAM2038 SC injectionPhase 31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Braeburn PharmaceuticalsCAM2038 SC injection
AlkermesXR-NTX
Clinical Trials (2)
Total enrollment: 428 patients across 2 trials
Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence
Start: Dec 2015Est. completion: Nov 2016428 patients
Phase 3Completed
Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)
Start: Jun 2015Est. completion: May 2019
Phase 3Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space